Crf2 receptor agonists and their use in therapy

IL300464A1Pending Publication Date: 2026-07-01SANOFI SA(FR)
0 Cites 0 Cited by

Patent Information

Application Number
IL300464
Authority / Receiving Office
IL · IL
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-08-19
Filing Date
2021-08-18
Publication Date
2026-07-01
Estimated Expiration
2041-08-18

AI Technical Summary

Technical Problem

Current CRF2 receptor agonists, such as urocortins, have a short half-life, limiting their therapeutic use, and there is a need for improved compounds with desirable efficacy, pharmacokinetic properties, and stability for the treatment and prevention of cardiovascular diseases, obesity, and diabetes.

Method used

Development of peptide compounds with specific amino acid sequences, including a modified lysine residue with an albumin-binding moiety, which exhibit improved CRF2 receptor agonism, stability, and solubility, allowing for subcutaneous delivery and prolonged therapeutic effects.

Benefits of technology

The peptide compounds demonstrate enhanced activity and selectivity at the CRF2 receptor, improved stability, and solubility, making them suitable for effective treatment and prevention of cardiovascular diseases, obesity, and diabetes, with potential for self-administration and improved patient management.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present disclosure provides compounds which are peptides comprising the amino acid sequence of the formula (I) disclosed herein or pharmaceutically acceptable salts thereof. The compounds act as agonists of the corticotropin-releasing factor receptor 2 (CRF2) and are useful in therapy, especially in the treatment or prevention of cardiovascular diseases, obesity and diabetes.
Need to check novelty before this filing date? Find Prior Art